株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腎線維症 : パイプライン分析

Kidney Fibrosis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251573
出版日 ページ情報 英文 131 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
腎線維症 : パイプライン分析 Kidney Fibrosis - Pipeline Review, H2 2016
出版日: 2016年10月12日 ページ情報: 英文 131 Pages
概要

腎臓の中で細胞外基質が蓄積されていくと、腎線維症を引き起こします。これは糸球体硬化症と尿細管間質性線維症が特徴的な進行性の疾患で、腎臓機能に対して有害作用を与えることもあります。 素因は、外傷、感染症、手術、環境要因、そして化学物質や放射線への被曝が挙げられます。 症候は、疼痛、排尿に関連した問題、吐き気と嘔吐などがあります。 薬物や腎臓移植で症状を管理します。

当レポートでは、腎線維症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

腎線維症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • AbbVie Inc.
  • Angion Biomedica Corp.
  • Bio-inRen
  • BioLineRx, Ltd.
  • BiOrion Technologies B.V.
  • Cellmid Limited
  • Evotec AG
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • GNI Group Ltd.
  • Intercept Pharmaceuticals, Inc.
  • Isarna Therapeutics GmbH
  • Lpath, Inc.
  • MorphoSys AG
  • ProMetic Life Sciences Inc.
  • Raptor Pharmaceuticals Corp.
  • Regulus Therapeutics Inc.
  • SciFluor Life Sciences, LLC

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ANG-3070
  • ANG-3586
  • ANG-4011
  • ANG-4021
  • BOT-191
  • BRN-1889
  • CAB-101
  • CGEN-856
  • CT-140
  • cysteamine DR
  • 線維症向け Galectin-3 阻害薬
  • 組織線維症治療薬
  • F-351
  • 高血圧性心筋症・腎線維症向け Smad7 活性化遺伝療法
  • GKT-136901
  • GRMD-02
  • ICG-001
  • INT-767
  • ISTH-0047
  • LJ-1888
  • Lpathomab
  • MOR-107
  • P-007
  • PBI-4050
  • PBI-4419
  • 肥満症・変形性関節症・腎線維症・アルポート症候群向け BMP-7 活性化タンパク質
  • SAR-339375
  • 線維症向け小分子
  • 肥満症・腎線維症向け サイクロフィリン D 阻害小分子
  • 腫瘍学・腎線維症・自己免疫疾患・線維症・神経変性疾患向け SphK2 阻害小分子
  • SOL-1
  • 腎線維症向け BMP7 受容体作動用合成ペプチド

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8537IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 21 and 7 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Kidney Fibrosis.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kidney Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Kidney Fibrosis - Overview
    • Pipeline Products for Kidney Fibrosis - Comparative Analysis
  • Kidney Fibrosis - Therapeutics under Development by Companies
  • Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Kidney Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Kidney Fibrosis - Products under Development by Companies
  • Kidney Fibrosis - Products under Investigation by Universities/Institutes
  • Kidney Fibrosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Angion Biomedica Corp.
    • Bio-inRen
    • BiOrion Technologies B.V.
    • Cellmid Limited
    • Epigen Biosciences, Inc.
    • Evotec AG
    • Galectin Therapeutics, Inc.
    • GenKyoTex S.A.
    • Intercept Pharmaceuticals, Inc.
    • Isarna Therapeutics GmbH
    • Lpath, Inc.
    • MorphoSys AG
    • Pharmaxis Limited
    • ProMetic Life Sciences Inc.
    • Raptor Pharmaceutical Corp.
    • Regulus Therapeutics Inc.
    • Symic Biomedical, Inc.
    • Tobira Therapeutics, Inc.
    • Vascular Biogenics Ltd.
  • Kidney Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3586 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-4021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BOT-191 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BRN-1889 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAB-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cysteamine DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GKT-136901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICG-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-0047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-1888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOR-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4419 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-4820 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-5033A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOL-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Kidney Fibrosis - Dormant Projects
  • Kidney Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
      • Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics
      • Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting
      • Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
      • Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
      • Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
      • Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
      • Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Kidney Fibrosis, H2 2016
  • Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Kidney Fibrosis - Pipeline by AbbVie Inc, H2 2016
  • Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
  • Kidney Fibrosis - Pipeline by Bio-inRen, H2 2016
  • Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
  • Kidney Fibrosis - Pipeline by Cellmid Limited, H2 2016
  • Kidney Fibrosis - Pipeline by Epigen Biosciences, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Evotec AG, H2 2016
  • Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by GenKyoTex S.A., H2 2016
  • Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Kidney Fibrosis - Pipeline by Lpath, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2016
  • Kidney Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
  • Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016
  • Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Kidney Fibrosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Kidney Fibrosis, H2 2016
  • Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top